In COVID-19 clinical update #66, Daniel Griffin covers treatment guidelines from IDSA, hospitalization of adolescents, estimating epidemiological dynamics from viral load distributions, incidence of infection according to baseline antibody status, assessment of reinfection in Italy, need for vaccination in previously infected individuals, assessment of protection against reinfection, antimicrobial use in hospitalized patients, effect of single dose ivermectin, and a trial of aspirin in hospitalized patients.
David joins TWiV to relate how his near-death experience with Castleman’s disease motivated him to found the Center for Cytokine Storm Treatment & Laboratory and the CORONA project to identify and track all treatments reported for COVID-19 in an open-source data repository.
TWiV reviews the new nomenclature for SARS-CoV-2 variants, effectiveness of Pfizer/BioNTech vaccine against variants, modified Moderna vaccine against variants, impact of COVID-19 interventions on influenza in China and the US, and binding of RaTG13 spike protein to ACE2 of multiple species.
In COVID-19 clinical update #65, Daniel Griffin summarizes effects of non-pharmaceutical interventions, updated summer camp guidance from CDC, serology testing not recommended by FDA, antigen tests during a music event, inhibition of vaccine immunogenicity by methotrexate, phase 3 trial results for colchicine, and small airway disease as a post-acute sequelae.
TWiV explains how cap-snatching, the priming of viral mRNA synthesis with fragments of host mRNAs, can lead to the synthesis of novel viral proteins.
Robert Garry joins TWiV to explain how the molecular biology of SARS-CoV-2 shows that it came from Nature and not a lab, including the receptor binding domain, the furin cleavage site, and the two lineages circulating in Wuhan wildlife markets.
In COVID-19 clinical update #64, Daniel Griffin covers new guidance from NY on day camps, mitigation and infection rates in schools, testing to sustain in person instruction, Moderna mRNA vaccine highly effective in adolescents, longer storage of Pfizer vaccine, FDA EUA for sotrovimab, and persistent illness in UK children.
Peter Daszak, Thea Kølsen Fischer, and Marion Koopmans, members of the WHO team investigating the origins of SARS-CoV-2 join TWiV to explain the work done by the committee during phase one, their conclusions, and the extent of work that remains to be done in phase two.
In COVID-19 clinical update #63, Daniel Griffin reviews cases at child care facilities, estimates of mRNA vaccine effectiveness, risk of reinfection in university students, enhanced antibody generation with extended interval of mRNA vaccination, no benefit of convalescent plasma in hospitalized patients, and risk of clinical sequelae after acute infection.
TWiV reveals that 2% of SARS-CoV-2−positive individuals carry 90% of the virus circulating in a college campus, and a nanoparticle vaccine that induces cross-reactive immunity against multiple pandemic and pre-emergent coronaviruses.